Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 9, 2012

PsiOxus Raises $34M to Take Oncolytic Virus Into Clinic

  • Technology commercialization and investment firm Imperial Innovations led a £22 million (about $34 million) funding round for PsiOxus Therapeutics. The financing will support Phase I and Phase II development of ColoAd1, PsiOxus’ chimeric oncolytic virus. The fundraising comprised £5.5 million each invested by Imperial Innovations and Invesco Perpetual, and new investors SR One and Lundbeckfond Ventures, who invested £11 million between them. Imperial Innovations now holds a 26% stake in PsiOxus.

    PsiOxus Therapeutics was formed in 2010 through the merger of Imperial College, London spin-out Myotec Therapeutics, and Hybrid Biosystems, which originally developed the adenovirus-based ColoAd1 in collaboration with Bayer Schering. The broad-spectrum oncolytic virus has been developed using evolutionary approaches, and will initially be developed for the treatment of metastatic colorectal cancer and primary hepatocellular carcinoma. Last September PsiOxus received a Translation Award from the Wellcome Trust worth up to £1.8 million to support clinical development of the viral vaccine candidate.

    PsiOxus’ lead clinical-stage candidate, MT-102, was originally developed by Myotec. The small molecule drug is an anabolic catabolic transforming agent (ACTA) in Phase II development for treating cancer therapy-related cachexia and sarcopenia.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »